Form 4: Acadia Healthcare CEO Christopher Hunter Reports Stock Transactions
SEC Form 4 Filing
Christopher H. Hunter, CEO of Acadia Healthcare Company, Inc., reports acquisition and disposal of company stock related to vesting of restricted stock units.
Summary
- Christopher H. Hunter, the CEO of Acadia Healthcare Company, Inc., filed a Form 4 detailing changes in his beneficial ownership of the company's stock.
- On February 27, 2025, Hunter acquired 6,672 shares of common stock upon the vesting of performance vesting restricted stock units awarded on April 11, 2022.
- He also acquired 13,124 shares earned based on 2024 performance under performance vesting restricted stock units awarded on May 9, 2023, which will be issued at the end of the three-year period.
- Additionally, he disposed of 16,995 shares at a price of $40.26.
- Following these transactions, Hunter beneficially owns 132,761 shares of Acadia Healthcare Company, Inc.
Sentiment
Score: 5
Explanation: The sentiment is neutral as the transactions are related to standard executive compensation practices. The sale of shares is not necessarily indicative of a negative outlook.
Positives
- The vesting of restricted stock units indicates that performance targets were met, which could be seen as a positive signal.
Negatives
- The disposal of 16,995 shares by the CEO could be interpreted negatively by some investors, although it may be part of a planned diversification strategy.
Risks
- Executive stock sales can sometimes be perceived as a lack of confidence in the company's future performance, potentially impacting investor sentiment.
Future Outlook
The shares earned based on 2024 performance under performance vesting restricted stock units awarded on May 9, 2023, will not be issued until the end of the three-year period under the restricted stock unit award.
Industry Context
Form 4 filings are routine disclosures for corporate insiders and are closely watched by investors for insights into management's perspective on the company's stock.
Comparison to Industry Standards
- Comparing Christopher Hunter's transactions to those of CEOs at similar healthcare companies like Universal Health Services (UHS) or HCA Healthcare (HCA) could provide context.
- For example, if CEOs at comparable companies are also exercising and selling stock options, it might suggest a broader trend in the industry related to executive compensation or personal financial planning.
- Analyzing the ratio of stock grants to sales among these executives could also reveal whether Hunter's actions are in line with industry norms.
Stakeholder Impact
- The transactions may have a minor impact on shareholder sentiment, depending on how they interpret the CEO's stock disposal.
Key Dates
| Date | Description |
|---|---|
| April 11, 2022 | Date of award of performance vesting restricted stock units related to the vesting of 6,672 shares. |
| May 9, 2023 | Date of award of performance vesting restricted stock units related to the earning of 13,124 shares based on 2024 performance. |
| February 27, 2025 | Date of stock acquisition and disposal transactions. |
| February 28, 2025 | Date of signature on the Form 4 filing. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.